Abstract
Type 2 diabetes mellitus (T2DM) is a progressive disease and as the disease progresses, insulin therapy becomes necessary in at least 50% of patients with T2DM. The administration of very high insulin doses has inherent challenges including weight gain, absorption problems with high volume of insulin as well as compromising on patient acceptance, comfort and compliance. Thus, it is important to have treatment options that combine insulin-sparing agents with insulin to minimize both insulin volume and side effects. The glucagon-like peptide-1 receptor agonists/analogues (GLP-1 RAs) provide an attractive option for the same. Here, I present two cases wherein addition of liraglutide to high dose insulin therapy, relatively late in the disease process, led to complete cessation of insulin therapy as well as weight loss.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Current Research in Diabetes & Obesity Journal
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
